SLE is a chronic autoimmune condition that affects around 1 in 1,000 people in the UK and is around six times more common in women than men
SGLT2 inhibitors have clear protective effects against heart failure and chronic kidney disease, while GLP-1 receptor agonists can reduce the risk of heart attack, stroke, and also kidney disease - as recently demonstrated in the landmark FLOW trial, Neuen concluded
This report highlights the crucial developments along with other events happening in the market which are marking on the growth and opening doors for future growth in the coming years
states and Washington D.C., which also speaks to its compliance with varying state healthcare regulations
Some users may indeed respond better to one form based on genetic or metabolic factors
Ten microliters of cell lysate was transferred to a white 384-well OptiPlate